BioTelemetry (BEAT) Study Shows Apple Positioning iWatch As Screening Device Rather Than Medical Grade - Suntrust

March 18, 2019 7:31 AM
SunTrust analyst Bruce Nudell reiterated a Buy rating and $80.00 price target on BioTelemetry (NASDAQ: BEAT) after results from the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)


Analyst Comments